Expanding the landscape of oncogenic drivers and treatment options in acral and mucosal melanomas by targeted genomic profiling
Jacqueline A. Turner,Robert J. Van Gulick,William A. Robinson,Tariq Mughal,Richard P. Tobin,Morgan L. MacBeth,Blair Holman,Anthony Classon,Stacey M. Bagby,Betelehem W. Yacob,Sarah J. Hartman,Ian Silverman,Victoria M. Vorwald,Nicholas Gorden,Rita Gonzalez,Laurie M. Gay,Siraj M. Ali,Adam Benson,Vincent A. Miller,Jeffrey S. Ross,Todd M. Pitts,Matthew J. Rioth,Karl D. Lewis,Theresa Medina,Martin D. McCarter,Rene Gonzalez,Kasey L. Couts
DOI: https://doi.org/10.1002/ijc.35087
2024-07-14
International Journal of Cancer
Abstract:What's new? Rare melanomas are clinically managed as cutaneous melanomas, despite being separate diseases, often with distinct causal factors, that typically fail traditional therapies. In particular, acral and mucosal (A/M) melanomas possess unique genomic features, different from those of cutaneous melanoma. In this study, using pre‐clinical models of A/M melanoma, the authors identified unique genetic alterations and therapeutic vulnerabilities, including an inactivating NF2 fusion with sensitivity to dasatinib in mice with melanoma patient‐derived xenografts. The newly identified molecular differences between cutaneous and A/M melanomas emphasize the need for diagnostic and treatment regimens tailored to patients with rare, difficult‐to‐treat melanomas. Despite advancements in treating cutaneous melanoma, patients with acral and mucosal (A/M) melanomas still have limited therapeutic options and poor prognoses. We analyzed 156 melanomas (101 cutaneous, 28 acral, and 27 mucosal) using the Foundation One cancer‐gene specific clinical testing platform and identified new, potentially targetable genomic alterations (GAs) in specific anatomic sites of A/M melanomas. Using novel pre‐clinical models of A/M melanoma, we demonstrate that several GAs and corresponding oncogenic pathways associated with cutaneous melanomas are similarly targetable in A/M melanomas. Other alterations, including MYC and CRKL amplifications, were unique to A/M melanomas and susceptible to indirect targeting using the BRD4 inhibitor JQ1 or Src/ABL inhibitor dasatinib, respectively. We further identified new, actionable A/M‐specific alterations, including an inactivating NF2 fusion in a mucosal melanoma responsive to dasatinib in vivo. Our study highlights new molecular differences between cutaneous and A/M melanomas, and across different anatomic sites within A/M, which may change clinical testing and treatment paradigms for these rare melanomas.
oncology